Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
GAITHERSBURG, Md., Nov. 02, 2016 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November 9, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities. Please be sure to join the webcast in order to access the slide presentation.
Conference call details are as follows:
| Date: | Wednesday, November 9, 2016 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call replay:
| Dates: | Starting at 8:30 p.m. ET, November 9, 2016 until November 16, 2016 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000
